Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

Online First

May 13, 2021

Psoriatic arthritis
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

Philip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, Michael E Luggen, Proton Rahman, Siba P Raychaudhuri, Richard C Chou, Alan M Mendelsohn, Stephen J Rozzo, Alice Gottlieb

doi: 10.1136/annrheumdis-2020-219014
Correspondence response
Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Rosenbaum et al
Free

Kimme L Hyrich, Martin Schäfer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F Mateus, Saskia Lawson-Tovey, Milena Gianfrancesco, Philip C Robinson, Jinoos Yazdany, Pedro M Machado

doi: 10.1136/annrheumdis-2021-220613
Correspondence
Correspondence on ‘Warfarin use and risk of knee and hip replacements’
Free

Chao Cheng, Fangjie Zhang

doi: 10.1136/annrheumdis-2021-220580
Correspondence response
Response to: ‘Correspondence on ‘Warfarin use and risk of knee and hip replacements’’ by Cheng and Zhang
Free

Tuhina Neogi, Christine Peloquin, Priyanka Ballal, Cindy Germaine Boer

doi: 10.1136/annrheumdis-2021-220601
Correspondence
Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’
Free

James Todd Rosenbaum, Michael H Weisman, Cassie Shafer, Elin Aslanyan, Richard A Howard, Kimberly Ogle, Hedley Hamilton, John D Reveille, Kevin L Winthrop, Dongseok Choi

doi: 10.1136/annrheumdis-2021-220588

May 12, 2021

Correspondence
Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’
Free

Desiree Tampe, Peter Korsten, Samy Hakroush, Martin Sebastian Winkler, Björn Tampe

doi: 10.1136/annrheumdis-2021-220382
Correspondence response
Response to: ‘Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’’ by Tampe et al
Free

Marcia A Friedman, Kevin L Winthrop

doi: 10.1136/annrheumdis-2021-220398
Inflammatory arthritis
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Ulf M Geisen, Dennis K Berner, Florian Tran, Melike Sümbül, Lena Vullriede, Maria Ciripoi, Hayley M Reid, Annika Schaffarzyk, Ann C Longardt, Jeanette Franzenburg, Paula Hoff, Jan H Schirmer, Rainald Zeuner, Anette Friedrichs, Andrea Steinbach, Christine Knies, Robert DH Markewitz, Peter J Morrison, Sascha Gerdes, Stefan Schreiber, Bimba F Hoyer

doi: 10.1136/annrheumdis-2021-220272

May 11, 2021

Letter
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
Free

Robert Spiera, Sarah Jinich, Deanna Jannat-Khah

doi: 10.1136/annrheumdis-2021-220604
Recommendation
2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

Elena Nikiphorou, Eduardo José Ferreira Santos, Andrea Marques, Peter Böhm, Johannes WJ Bijlsma, Claire Immediato Daien, Bente Appel Esbensen, Ricardo J O Ferreira, George E Fragoulis, Pat Holmes, Hayley McBain, George S Metsios, Rikke Helene Moe, Tanja A Stamm, Annettede de Thurah, Condruta Zabalan, Loreto Carmona, Ailsa Bosworth

doi: 10.1136/annrheumdis-2021-220249

May 10, 2021

Viewpoint
Primary and secondary non-response: in need of operational definitions in observational studies

Enriqueta Vallejo-Yagüe, Edward C Keystone, Sreemanjari Kandhasamy, Raphael Micheroli, Axel Finckh, Andrea Michelle Burden

doi: 10.1136/annrheumdis-2021-220202
Letter
Effects of face masks on oxygen saturation and functional measures in patients with connective tissue disorder-associated interstitial lung disease
Free

Anuroopa Vijayan, Sakir Ahmed, Sneha Joseph, Aswathy Sukumaran, Subin Ahmed, Padmanabha Shenoy

doi: 10.1136/annrheumdis-2021-220230

May 07, 2021

Correspondence response
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’’ by Smerilli et al
Free

Roberta Priori, Greta Pellegrino, Serena Colafrancesco, Cristiano Alessandri, Fulvia Ceccarelli, Manuela Di Franco, Valeria Riccieri, Rossana Scrivo, Antonio Sili Scavalli, Francesca Romana Spinelli, Fabrizio Conti

doi: 10.1136/annrheumdis-2021-220612
Correspondence
Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’
Free

Gianluca Smerilli, Edoardo Cipolletta, Erica Moscioni, Francesca Francioso, Anna Maria Risa, Vincenzo Maccarrone, Davide Zompa, Andrea Di Matteo, Marco Di Carlo, Rossella De Angelis, Fausto Salaffi, Emilio Filippucci, Walter Grassi

doi: 10.1136/annrheumdis-2021-220586
Osteoarthritis
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study

Felix Eckstein, Marc C Hochberg, Hans Guehring, Flavie Moreau, Victor Ona, Asger Reinstrup Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Benjamin Daelken, Oliver Guenther, Christoph Ladel, Martin Michaelis, Philip G Conaghan

doi: 10.1136/annrheumdis-2020-219181
Letter
Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis

Satoshi Takanashi, Yuko Kaneko, Tsutomu Takeuchi

doi: 10.1136/annrheumdis-2021-220315

May 06, 2021

Spondyloarthritis
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)

Robert BM Landewé, Lianne S Gensler, Denis Poddubnyy, Proton Rahman, Maja Hojnik, Xiaoqi Li, Soyi Liu Leage, David Adams, Hilde Carlier, Filip Van den Bosch on behalf of the COAST-Y study group

doi: 10.1136/annrheumdis-2020-219717
Letter
Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation
Free

Marlou T H F Janssen, Sofia Ramiro, Robert B M Landewé, César Magro-Checa, Rémy L M Mostard

doi: 10.1136/annrheumdis-2021-220040
Inflammatory arthritis
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

David Simon, Koray Tascilar, Filippo Fagni, Gerhard Krönke, Arnd Kleyer, Christine Meder, Raja Atreya, Moritz Leppkes, Andreas E Kremer, Andreas Ramming, Milena L Pachowsky, Florian Schuch, Monika Ronneberger, Stefan Kleinert, Axel J Hueber, Karin Manger, Bernhard Manger, Carola Berking, Michael Sticherling, Markus F Neurath, Georg Schett

doi: 10.1136/annrheumdis-2021-220461
Spondyloarthritis
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial

Anna Molto, Clementina López-Medina, Filip E Van den Bosch, Annelies Boonen, Casper Webers, Emanuelle Dernis, Floris A van Gaalen, Martin Soubrier, Pascal Claudepierre, Athan Baillet, Mirian Starmans-Kool, Anneke Spoorenberg, Peggy Jacques, Philippe Carron, Rik Joos, Jan Lenaerts, Laure Gossec, Sophie Pouplin, Adeline Ruyssen-Witrand, Laetitia Sparsa, Astrid van Tubergen, Désirée van der Heijde, Maxime Dougados

doi: 10.1136/annrheumdis-2020-219585
Letter
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
Free

Michael Markus Bonelli, Daniel Mrak, Thomas Perkmann, Helmuth Haslacher, Daniel Aletaha

doi: 10.1136/annrheumdis-2021-220408

April 29, 2021

Pain
Genome-wide association study identifies RNF123 locus as associated with chronic widespread musculoskeletal pain

Md Shafiqur Rahman, Bendik S Winsvold, Sergio O Chavez Chavez, Sigrid Børte, Yakov A Tsepilov, Sodbo Zh Sharapov, HUNT All-In Pain, Yurii S Aulchenko, Knut Hagen, Egil A Fors, Kristian Hveem, John Anker Zwart, Joyce B van Meurs, Maxim B Freidin, Frances MK Williams

doi: 10.1136/annrheumdis-2020-219624
Psoriatic arthritis
Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial

Maja Skov Kragsnaes, Jens Kjeldsen, Hans Christian Horn, Heidi Lausten Munk, Jens Kristian Pedersen, Søren Andreas Just, Palle Ahlquist, Finn Moeller Pedersen, Maarten de Wit, Sören Möller, Vibeke Andersen, Karsten Kristiansen, Dorte Kinggaard Holm, Hanne Marie Holt, Robin Christensen, Torkell Ellingsen

doi: 10.1136/annrheumdis-2020-219511
Treatment
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial

Hafsah Nabi, Stylianos Georgiadis, Anne Gitte Loft, Oliver Hendricks, Marlene Andersen, Stavros Chrysidis, Ada Colic, Kamilla Danebod, Mohamad Redha Hussein, Maren Høgberget Kalisz, Salome Kristensen, Niels Lomborg, Natalia Manilo, Heidi Lausten Munk, Jens Kristian Pedersen, Johnny Lillelund Raun, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland, Bente Glintborg

doi: 10.1136/annrheumdis-2021-219951

April 27, 2021

Correspondence response
Response to: ‘Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’’ by Roongta et al
Free

Veerle F A M Derksen, Diane van der Woude

doi: 10.1136/annrheumdis-2021-220516
Viewpoint
EULAR COVID-19 registry: lessons learnt and future considerations
Free

Saskia Lawson-Tovey, Anja Strangfeld, Kimme L Hyrich, Loreto Carmona, Diana Rodrigues, Laure Gossec, Elsa F Mateus, Pedro M Machado

doi: 10.1136/annrheumdis-2021-220319
Spondyloarthritis
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

Atul Deodhar, Paula Sliwinska-Stanczyk, Huji Xu, Xenofon Baraliakos, Lianne S Gensler, Dona Fleishaker, Lisy Wang, Joseph Wu, Sujatha Menon, Cunshan Wang, Oluwaseyi Dina, Lara Fallon, Keith S Kanik, Désirée van der Heijde

doi: 10.1136/annrheumdis-2020-219601
Correspondence
Correspondence on ‘EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs’
Free

Serena Bugatti, Silvia Balduzzi, Ludovico De Stefano, Antonio Manzo, Blerina Xoxi, Laura Bogliolo, Sara Monti, Paolo Delvino, Carlomaurizio Montecucco

doi: 10.1136/annrheumdis-2021-220541
Correspondence response
Response to: ‘Correspondence on ‘EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs’’ by Bugatti et al
Free

Johannes W J Bijlsma on behalf of EULAR COVID-19 Task Force

doi: 10.1136/annrheumdis-2021-220564
Correspondence
Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’
Free

Rashmi Roongta, Arghya Chattopadhyay, Alakendu Ghosh

doi: 10.1136/annrheumdis-2021-220479

April 26, 2021

Autoimmunity
Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients

Uriel Trahtemberg, Robert Rottapel, Claudia C Dos Santos, Arthur S Slutsky, Andrew Baker, Marvin J Fritzler

doi: 10.1136/annrheumdis-2021-220206
Correspondence
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’
Free

Aimilios Kaklamanos, Panagiotis Karamichalos, Panayiotis G Vlachoyiannopoulos, Athanasios G Tzioufas

doi: 10.1136/annrheumdis-2021-220411
Systemic sclerosis
X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc)

Christina Bergmann, Ludwig Hallenberger, Sara Chenguiti Fakhouri, Benita Merlevede, Amelie Brandt, Clara Dees, Honglin Zhu, Ariella Zehender, Xiang Zhou, Annemarie Schwab, Chih-Wei Chen, Andrea Hermina Györfi, Alexandru Emil Matei, Debomita Chakraborty, Thuong Trinh-Minh, Simon Rauber, Roland Coras, Aline Bozec, Alexander Kreuter, Mirjana Ziemer, Georg Schett, Jörg H W Distler

doi: 10.1136/annrheumdis-2020-219822
Osteoarthritis
Linking chondrocyte and synovial transcriptional profile to clinical phenotype in osteoarthritis

Julia Steinberg, Lorraine Southam, Andreas Fontalis, Matthew J Clark, Raveen L Jayasuriya, Diane Swift, Karan M Shah, Roger A Brooks, Andrew W McCaskie, Jeremy Mark Wilkinson, Eleftheria Zeggini

doi: 10.1136/annrheumdis-2020-219760
Correspondence response
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanos et al
Free

Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé

doi: 10.1136/annrheumdis-2021-220474

April 21, 2021

Letter
Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis

Federica Bello, Federica Maritati, Antonella Radice, Renato Alberto Sinico, Giacomo Emmi, Augusto Vaglio

doi: 10.1136/annrheumdis-2021-220111
Correspondence
Correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’
Free

Hercílio Martelli Júnior, Nelson Pereira Marques, Nádia Carolina Teixeira Marques, Edson Gomes de Lucena, Daniella Reis B Martelli, Eduardo A Oliveira

doi: 10.1136/annrheumdis-2021-220410

April 20, 2021

Spondyloarthritis
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis

Zhixiu Li, Xin Wu, Paul J Leo, Erika De Guzman, Nurullah Akkoc, Maxime Breban, Gary J Macfarlane, Mahdi Mahmoudi, Helena Marzo-Ortega, Lisa K Anderson, Lawrie Wheeler, Chung-Tei Chou, Andrew A Harrison, Simon Stebbings, Gareth T Jones, So-Young Bang, Geng Wang, Ahmadreza Jamshidi, Elham Farhadi, Jing Song, Li Lin, Mengmeng Li, James Cheng-Chung Wei, Nicholas G Martin, Margaret J Wright, MinJae Lee, Yuqin Wang, Jian Zhan, Jin-San Zhang, Xiaobing Wang, Zi-Bing Jin, Michael H Weisman, Lianne S Gensler, Michael M Ward, Mohammad Hossein Rahbar, Laura Diekman, Tae-Hwan Kim, John D Reveille, Bryan Paul Wordsworth, Huji Xu, Matthew A Brown TCRI AS Group

doi: 10.1136/annrheumdis-2020-219446

April 15, 2021

Spondyloarthritis
Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis

Zihao Li, Siwen Chen, Haowen Cui, Xiang Li, Dongying Chen, Wenjun Hao, Jianru Wang, Zemin Li, Zhaomin Zheng, Zhongping Zhang, Hui Liu

doi: 10.1136/annrheumdis-2021-220002

April 14, 2021

Spondyloarthritis
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

James Cheng-Chung Wei, Tae-Hwan Kim, Mitsumasa Kishimoto, Naoki Ogusu, Haeyoun Jeong, Shigeto Kobayashi 4827-006 study group

doi: 10.1136/annrheumdis-2020-219406

April 13, 2021

Letter
Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs
Free

Lotte van Ouwerkerk, Andrea E van der Meulen-de Jong, Maarten K Ninaber, Y K Onno Teng, Tom WJ Huizinga, Cornelia F Allaart

doi: 10.1136/annrheumdis-2021-219958
Letter
Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy
Free

Francesca Ingegnoli, Gilberto Cincinelli, Angela Flavia Luppino, Ennio Giulio Favalli, Annalisa Orenti, Patrizia Boracchi, Roberto Caporali

doi: 10.1136/annrheumdis-2021-220142

April 09, 2021

Correspondence
Correspondence on ‘Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study’
Free

Liang En Wee, Edwin Philip Conceicao, Jing Yuan Tan, Julian Thumboo, Indumathi Venkatachalam

doi: 10.1136/annrheumdis-2021-220462

April 08, 2021

Inflammatory arthritis
EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis

Annelies Boonen, Polina Putrik, Mary Lucy Marques, Alessia Alunno, Lydia Abasolo, Dorcas Beaton, Neil Betteridge, Mathilda Bjørk, Maarten Boers, Boryana Boteva, Bruno Fautrel, Francis Guillemin, Elsa F Mateus, Elena Nikiphorou, Márta Péntek, Fernando Pimentel Santos, Johannes L Severens, Suzanne M M Verstappen, Karen Walker-Bone, Johan Karlsson Wallman, Marieke M ter Wee, René Westhovens, Sofia Ramiro

doi: 10.1136/annrheumdis-2020-219523
Crystal arthropathies
Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank

Gabriela Sandoval-Plata, Kevin Morgan, Abhishek Abhishek

doi: 10.1136/annrheumdis-2020-219796

April 07, 2021

Rheumatoid arthritis
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting

Yusuke Miyazaki, Kazuhisa Nakano, Shingo Nakayamada, Satoshi Kubo, Yoshino Inoue, Yoshihisa Fujino, Yoshiya Tanaka

doi: 10.1136/annrheumdis-2020-219699

April 02, 2021

Rheumatoid arthritis
Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020

Wenhui Xie, Hong Huang, Guangtao Li, Yanjie Hao, Yanni Gui, Yu Wang, Xuerong Deng, Juan Zhao, Yan Geng, LanLan Ji, Xiaohui Zhang, Zhibo Song, Zhuoli Zhang

doi: 10.1136/annrheumdis-2021-220112
Rheumatoid arthritis
Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial

Veerle Stouten, René Westhovens, Sofia Pazmino, Diederik De Cock, Kristien Van der Elst, Johan Joly, Delphine Bertrand, Patrick Verschueren

doi: 10.1136/annrheumdis-2020-219825
Correspondence
Correspondence on ‘Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine-learning-based model to assist the diagnosis of systemic lupus erythematosus’
Free

Ezgi Deniz Batu, Ummusen Kaya Akca, Ozge Basaran, Yelda Bilginer, Seza Ozen

doi: 10.1136/annrheumdis-2021-220246
Correspondence response
Response to: ‘Correspondence on ‘Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus’ by Batu et al
Free

Christina Adamichou, George Bertsias

doi: 10.1136/annrheumdis-2021-220262

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online First

May 13, 2021

May 12, 2021

May 11, 2021

May 10, 2021

May 07, 2021

May 06, 2021

April 29, 2021

April 27, 2021

April 26, 2021

April 21, 2021

April 20, 2021

April 15, 2021

April 14, 2021

April 13, 2021

April 09, 2021

April 08, 2021

April 07, 2021

April 02, 2021

Pages